back to conferences

17th Clinical Trials on Alzheimer’s Disease (CTAD)

date

October 29 - November 1, 2024

location

Madrid, Spain

Quanterix and Lucent Diagnostics: Advancing Alzheimer’s Disease from Discovery to Diagnostics Together 

We’re thrilled to invite you to join Quanterix and Lucent Diagnostics, a Quanterix brand, at CTAD 2024! Together we’re contributing to the ongoing advancements in Alzheimer’s research, from discovery to diagnostics, with innovative solutions that are enhancing patient care.  

Join us at CTAD 2024 to explore the latest developments and learn more about the breakthroughs that are shaping the future of Alzheimer’s diagnostics and treatment. 

Exclusive Fireside Chat & Networking Reception Featuring Industry Leaders

One of the highlights of CTAD 2024 will be our exclusive Fireside Chat, featuring Dr. Henrik Zetterberg. Where he will explore insights on the latest advancements in research.

Following the Fireside Chat will be a networking event, offering the perfect opportunity to connect with industry leaders and peers passionate about Alzheimer’s research and diagnostics.

Fireside Chat & Networking Reception Details

Date: October 30, 2024

Time: 6:30 pm CET

Location: The Lounge Bar, Madrid Marriott Auditorium Hotel & Conference Center

Join a live discussion on the latest advancements and trends in the fight against Alzheimer’s disease, featuring expert insights from Henrik Zetterberg. Spaces are limited, so be sure to register now to secure your spot!

REGISTER NOW

Introducing LucentAD Complete™

At CTAD 2024, we’re excited to introduce LucentAD Complete, a best-in-class, ultrasensitive, non-invasive blood test for patients being evaluated for Alzheimer’s Disease. Powered by Quanterix’s digital Simoa® technology, LucentAD Complete offers a simple blood draw approach to diagnostics by analyzing key biomarkers such as:

  • p-Tau 217
  • NfL
  • GFAP*
  • Ab42/40

LucentAD Complete significantly reduces the intermediate zone of a two-cutoff p-Tau 217 test from 31.2% to just 12%, while maintaining high diagnostic accuracy above 90%.1

Healthcare providers can expect one result for all patients tested with LucentAD Complete, providing more answers for more patients than ever before.

*GFAP is offered pursuant to a license from Banyan Biomarkers, Inc.  Banyan GFAP® is a registered trademark of Banyan Biomarkers

1Wilson D, Khare M, Wolfe M, et al. Multi-marker approach to reducing the intermediate range of a high accuracy 2-cut-off plasma p-Tau 217 test for amyloid detection. Poster presented at: Alzheimer’s Association International Conference (AAIC); July 30, 2024; Philadelphia, PA.

Join Quanterix and Lucent Diagnostics at CTAD 2024 and be part of the conversation that’s changing the future of Alzheimer’s diagnosis and care. We hope to see you there!

Simoa® Poster Session Details

  • P127: Fully Automated Ultrasensitive Simoa Assay for Brain-Derived Tau: Enhancing the Characterization of Alzheimer’s Disease-Related Neurodegeneration in Blood
    Poster Session 2: From Thursday, October 31 – 7:15 a.m. to Thursday, October 31 – 5:00 p.m.
  • P139: 2-step multi-marker algorithm to reduce the intermediate range of a high accuracy plasma p-tau 217 test for amyloid detection
    Poster Session 2: From Thursday, October 31 – 7:15 a.m. to Thursday, October 31 – 5:00 p.m.

Resources